Evidence map›Paper›PMID 42136571›Full record

ArticleFrontiers in clinical diabetes and healthcare2026

Effects of canagliflozin on kidney resistive index and oxygenation in patients with type 2 diabetes: findings obtained with ultrasonography and blood oxygenation level-dependent MRI.

Hideki Uedono, Katsuhito Mori, Tsutomu Inoue, Yuri Machiba, Fumiyuki Morioka, Shinya Nakatani, Akihiro Tsuda, Hirokazu Okada, Masanori Emoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in clinical diabetes and healthcare, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hideki UedonoDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Katsuhito MoriDepartment of Endocrinology, Metabolism and Diabetes, Kindai University Nara Hospital, Nara, Japan.
Tsutomu InoueDepartment of Nephrology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Yuri MachibaDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Fumiyuki MoriokaDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Shinya NakataniDepartment of Nephrology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Akihiro TsudaDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Hirokazu OkadaDepartment of Nephrology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Masanori EmotoDepartment of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Details regarding kidney-protective mechanisms of sodium-glucose cotransporter 2 (SGLT2) inhibitors remain unclear. High kidney resistive index (RI), evaluated by Doppler ultrasonography, and low T Methods: Thirteen patients with type 2 diabetes (T2D) were analyzed. RI was determined at screening and on Day 5 (D5) following administration of Cana, while BOLD MRI was performed on D0, D1 (administration day), and D5. Cortical T Results: Cana significantly decreased RI, while ROI findings showed increased T Conclusion: Short-term Cana treatment improved RI and kidney oxygenation in patients with T2D. The inverse correlation found between changes in RI and T

Indexed as

BOLD MRIcanagliflozinkidney oxygenationresistive indexSGLT2 inhibitor

Identifiers

PMID42136571
PMCPMC13167403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.